The short version of IGF-1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-26. Anything still debated is marked as such rather than presented as settled.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Requires reconstitution before use |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Storage, powder | 2 to 8 degrees Celsius | Protect from light and moisture |
| Storage, solution | Refrigerated, short term | Use promptly after reconstitution |
| Common assays | Reversed-phase HPLC and mass spectrometry | Purity and identity respectively |
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Before the election, U.S. officials and former officials stated that foreign interference in the 2024 election was likely. Three major factors cited were "America's deepening domestic political crises, the collapse of controversial attempts to control political speech on social media, and the rise of generative AI". China, Russia, and Iran were identified as mounting influence operations and attempts to interfere with the 2024 election. U.S. intelligence officials described the efforts as part of broader efforts by authoritarian nations to use the internet to erode support for democracy.
Now EC 1.1.1.303, diacetyl reductase [(R)-acetoin forming] and EC 1.1.1.304, diacetyl reductase [(S)-acetoin forming] EC 1.1.1.6: glycerol dehydrogenase EC 1.1.1.7: propanediol-phosphate dehydrogenase EC 1.1.1.8: glycerol-3-phosphate dehydrogenase (NAD+) EC 1.1.1.9: D-xylulose reductase EC 1.1.1.10: L-xylulose reductase EC 1.1.1.11: D-arabinitol 4-dehydrogenase EC 1.1.1.12: L-arabinitol 4-dehydrogenase EC 1.1.1.13: L-arabinitol 2-dehydrogenase EC 1.1.1.14: L-iditol 2-dehydrogenase EC 1.1.1.15: D-iditol 2-dehydrogenase EC 1.1.1.16: galactitol 2-dehydrogenase EC 1.1.1.17: mannitol-1-phosphate 5-dehydrogenase EC 1.1.1.18: inositol 2-dehydrogenase EC 1.1.1.19: glucuronate reductase EC 1.1.1.20: glucuronolactone reductase EC 1.1.1.207: (-)-menthol dehydrogenase EC 1.1.1.208: (+)-neomenthol dehydrogenase EC 1.1.1.21: aldose reductase EC 1.1.1.22: UDP-glucose 6-dehydrogenase EC 1.1.1.222: (R)-4-hydroxyphenyllactate dehydrogenase EC 1.1.1.23: histidinol dehydrogenase| EC 1.1.1.24: quinate/shikimate dehydrogenase (NAD+) EC 1.1.1.25: shikimate dehydrogenase (NADP+) EC 1.1.1.26: glyoxylate reductase EC 1.1.1.27: L-lactate dehydrogenase EC 1.1.1.28: D-lactate dehydrogenase EC 1.1.1.29: glycerate dehydrogenase EC 1.1.1.30: 3-hydroxybutyrate dehydrogenase EC 1.1.1.31: 3-hydroxyisobutyrate dehydrogenase EC 1.1.1.32: mevaldate reductase EC 1.1.1.33: mevaldate reductase (NADPH) EC 1.1.1.34: hydroxymethylglutaryl-CoA reductase (NADPH) EC 1.1.1.35: 3-hydroxyacyl-CoA dehydrogenase EC 1.1.1.36: acetoacetyl-CoA reductase EC 1.1.1.37: malate dehydrogenase EC 1.1.1.38: malate dehydrogenase (oxaloacetate-decarboxylating) EC 1.1.1.39: malate dehydrogenase (decarboxylating) EC 1.1.1.40: malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+) EC 1.1.1.41: isocitrate dehydrogenase (NAD+) EC 1.1.1.42: isocitrate dehydrogenase (NADP+) EC 1.1.1.43: phosphogluconate 2-dehydrogenase EC 1.1.1.44: phosphogluconate dehydrogenase (NADP+-dependent, decarboxylating) EC 1.1.1.45: L-gulonate 3-dehydrogenase EC 1.1.1.46: L-arabinose 1-dehydrogenase EC 1.1.1.47: glucose 1-dehydrogenase [NAD(P)+)] EC 1.1.1.48: D-galactose 1-dehydrogenase EC 1.1.1.49: glucose-6-phosphate dehydrogenase (NADP+) EC 1.1.1.50: 3α-hydroxysteroid 3-dehydrogenase (Si-specific) EC 1.1.1.51: 3(or 17)β-hydroxysteroid dehydrogenase EC 1.1.1.52: 3α-hydroxycholanate dehydrogenase (NAD+) EC 1.1.1.53: 3α(or 20β)-hydroxysteroid dehydrogenase EC 1.1.1.54: allyl-alcohol dehydrogenase EC 1.1.1.55: lactaldehyde reductase (NADPH) EC 1.1.1.56: ribitol 2-dehydrogenase EC 1.1.1.57: fructuronate reductase EC 1.1.1.58: tagaturonate reductase EC 1.1.1.59: 3-hydroxypropionate dehydrogenase EC 1.1.1.60: 2-hydroxy-3-oxopropionate reductase EC 1.1.1.61: 4-hydroxybutyrate dehydrogenase EC 1.1.1.62: 17β-estradiol 17-dehydrogenase EC 1.1.1.63: testosterone 17β-dehydrogenase. Now EC 1.1.1.239, 3α(17β)-hydroxysteroid dehydrogenase (NAD+) EC 1.1.1.64: testosterone 17β-dehydrogenase (NADP+) EC 1.1.1.65: pyridoxine 4-dehydrogenase EC 1.1.1.66: ω-hydroxydecanoate dehydrogenase EC 1.1.1.67: mannitol 2-dehydrogenase EC 1.1.1.68: 5,10-methylenetetrahydrofolate reductase. Now EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.1.1.69: gluconate 5-dehydrogenase EC 1.1.1.70: D-glucuronolactone dehydrogenase. Now included with EC 1.2.1.3 aldehyde dehydrogenase (NAD+) EC 1.1.1.71: alcohol dehydrogenase [NAD(P)+] EC 1.1.1.72: glycerol dehydrogenase (NADP+) EC 1.1.1.73: octanol dehydrogenase EC 1.1.1.74: D-aminopropanol dehydrogenase (reaction due to EC 1.1.1.4 (R,R)-butanediol dehydrogenase) EC 1.1.1.75: (R)-aminopropanol dehydrogenase EC 1.1.1.76: (S,S)-butanediol dehydrogenase EC 1.1.1.77: lactaldehyde reductase EC 1.1.1.78: methylglyoxal reductase (NADH-dependent) EC 1.1.1.79: glyoxylate reductase (NADP+) EC 1.1.1.80: isopropanol dehydrogenase (NADP+) EC 1.1.1.81: hydroxypyruvate reductase EC 1.1.1.82: malate dehydrogenase (NADP+) EC 1.1.1.83: D-malate dehydrogenase (decarboxylating) EC 1.1.1.84: dimethylmalate dehydrogenase EC 1.1.1.85: 3-isopropylmalate dehydrogenase EC 1.1.1.86: ketol-acid reductoisomerase (NADP+) EC 1.1.1.87: homoisocitrate dehydrogenase EC 1.1.1.88: hydroxymethylglutaryl-CoA reductase EC 1.1.1.89: dihydroxyisovalerate dehydrogenase (isomerizing). Now included with EC 1.1.1.86 ketol-acid reductoisomerase EC 1.1.1.90: aryl-alcohol dehydrogenase EC 1.1.1.91: aryl-alcohol dehydrogenase (NADP+) EC 1.1.1.92: oxaloglycolate reductase (decarboxylating) EC 1.1.1.93: tartrate dehydrogenase EC 1.1.1.94: glycerol-3-phosphate dehydrogenase [NAD(P)+] EC 1.1.1.95: phosphoglycerate dehydrogenase EC 1.1.1.96: diiodophenylpyruvate reductase EC 1.1.1.97: 3-hydroxybenzyl-alcohol dehydrogenase EC 1.1.1.98: (R)-2-hydroxy-fatty-acid dehydrogenase EC 1.1.1.99: (S)-2-hydroxy-fatty-acid dehydrogenase EC 1.1.1.100: 3-oxoacyl-[acyl-carrier-protein] reductase EC 1.1.1.101: acylglycerone-phosphate reductase EC 1.1.1.102: 3-dehydrosphinganine reductase EC 1.1.1.103: L-threonine 3-dehydrogenase EC 1.1.1.104: 4-oxoproline reductase EC 1.1.1.105: all-trans-retinol dehydrogenase (NAD+) EC 1.1.1.106: pantoate 4-dehydrogenase EC 1.1.1.107: pyridoxal 4-dehydrogenase EC 1.1.1.108: carnitine 3-dehydrogenase EC 1.1.1.109: Now EC 1.3.1.28, 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase EC 1.1.1.110: aromatic 2-oxoacid reductase EC 1.1.1.111: 3-(imidazol-5-yl)lactate dehydrogenase EC 1.1.1.112: indanol dehydrogenase EC 1.1.1.113: L-xylose 1-dehydrogenase EC 1.1.1.114: apiose 1-reductase EC 1.1.1.115: ribose 1-dehydrogenase (NADP+) EC 1.1.1.116: D-arabinose 1-dehydrogenase (NAD+) EC 1.1.1.117: D-arabinose 1-dehydrogenase [NAD(P)+] EC 1.1.1.118: glucose 1-dehydrogenase (NAD+) EC 1.1.1.119: glucose 1-dehydrogenase (NADP+) EC 1.1.1.120: galactose 1-dehydrogenase (NADP+) EC 1.1.1.121: aldose 1-dehydrogenase (NAD+) EC 1.1.1.122: D-threo-aldose 1-dehydrogenase EC 1.1.1.123: sorbose 5-dehydrogenase (NADP+) EC 1.1.1.124: fructose 5-dehydrogenase (NADP+) EC 1.1.1.125: 2-deoxy-D-gluconate 3-dehydrogenase EC 1.1.1.126: 2-dehydro-3-deoxy-D-gluconate 6-dehydrogenase EC 1.1.1.127: 2-dehydro-3-deoxy-D-gluconate 5-dehydrogenase EC 1.1.1.128: The reaction described is covered by EC 1.1.1.264, L-idonate 5-dehydrogenase. EC 1.1.1.129: L-threonate 3-dehydrogenase EC 1.1.1.130: 3-dehydro-L-gulonate 2-dehydrogenase EC 1.1.1.131: mannuronate reductase EC 1.1.1.132: GDP-mannose 6-dehydrogenase EC 1.1.1.133: dTDP-4-dehydrorhamnose reductase EC 1.1.1.134: dTDP-6-deoxy-L-talose 4-dehydrogenase (NADP+) EC 1.1.1.135: GDP-6-deoxy-D-talose 4-dehydrogenase EC 1.1.1.136: UDP-N-acetylglucosamine 6-dehydrogenase EC 1.1.1.137: ribitol-5-phosphate 2-dehydrogenase EC 1.1.1.138: mannitol 2-dehydrogenase (NADP+) EC 1.1.1.139: polyol dehydrogenase (NADP+). Now included with EC 1.1.1.21 aldehyde reductase EC 1.1.1.140: sorbitol-6-phosphate 2-dehydrogenase EC 1.1.1.141: 15-hydroxyprostaglandin dehydrogenase (NAD+) EC 1.1.1.142: D-pinitol dehydrogenase EC 1.1.1.143: sequoyitol dehydrogenase EC 1.1.1.144: perillyl-alcohol dehydrogenase EC 1.1.1.145: 3β-hydroxy-Δ5-steroid dehydrogenase EC 1.1.1.146: 11β-hydroxysteroid dehydrogenase EC 1.1.1.147: 16α-hydroxysteroid dehydrogenase EC 1.1.1.148: estradiol 17α-dehydrogenase EC 1.1.1.149: 20α-hydroxysteroid dehydrogenase EC 1.1.1.150: 21-hydroxysteroid dehydrogenase (NAD+) EC 1.1.1.151: 21-hydroxysteroid dehydrogenase (NADP+) EC 1.1.1.152: 3α-hydroxy-5β-androstane-17-one 3α-dehydrogenase EC 1.1.1.153: sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming) EC 1.1.1.154: ureidoglycolate dehydrogenase EC 1.1.1.155: homoisocitrate dehydrogenase. The enzyme is identical to EC 1.1.1.87, homoisocitrate dehydrogenase EC 1.1.1.156: glycerol 2-dehydrogenase (NADP+) EC 1.1.1.157: 3-hydroxybutyryl-CoA dehydrogenase EC 1.1.1.158: Now EC 1.3.1.98, UDP-N-acetylmuramate dehydrogenase EC 1.1.1.159: 7α-hydroxysteroid dehydrogenase EC 1.1.1.160: dihydrobunolol dehydrogenase EC 1.1.1.161: The activity is part of EC 1.14.13.15, cholestanetriol 26-monooxygenase EC 1.1.1.162: erythrulose reductase EC 1.1.1.163: cyclopentanol dehydrogenase EC 1.1.1.164: hexadecanol dehydrogenase EC 1.1.1.165: 2-alkyn-1-ol dehydrogenase EC 1.1.1.166: hydroxycyclohexanecarboxylate dehydrogenase EC 1.1.1.167: hydroxymalonate dehydrogenase EC 1.1.1.168: 2-dehydropantolactone reductase (Re-specific) EC 1.1.1.169: 2-dehydropantoate 2-reductase EC 1.1.1.170: 3β-hydroxysteroid-4α-carboxylate 3-dehydrogenase (decarboxylating) EC 1.1.1.171: Now EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.1.1.172: 2-oxoadipate reductase EC 1.1.1.173: L-rhamnose 1-dehydrogenase EC 1.1.1.174: cyclohexane-1,2-diol dehydrogenase EC 1.1.1.175: D-xylose 1-dehydrogenase EC 1.1.1.176: 12α-hydroxysteroid dehydrogenase EC 1.1.1.177: glycerol-3-phosphate 1-dehydrogenase (NADP+) EC 1.1.1.178: 3-hydroxy-2-methylbutyryl-CoA dehydrogenase EC 1.1.1.179: D-xylose 1-dehydrogenase (NADP+, D-xylono-1,5-lactone-forming) EC 1.1.1.180: Now included with EC 1.1.1.131 mannuronate reductase EC 1.1.1.181: cholest-5-ene-3β,7α-diol 3β-dehydrogenase EC 1.1.1.182: Now included with EC 1.1.1.198 (+)-borneol dehydrogenase, EC 1.1.1.227 (-)-borneol dehydrogenase and EC 1.1.1.228 (+)-sabinol dehydrogenase EC 1.1.1.183: geraniol dehydrogenase (NADP+) EC 1.1.1.184: carbonyl reductase (NADPH) EC 1.1.1.185: L-glycol dehydrogenase EC 1.1.1.186: dTDP-galactose 6-dehydrogenase EC 1.1.1.187: GDP-4-dehydro-D-rhamnose reductase EC 1.1.1.188: prostaglandin-F synthase EC 1.1.1.189: prostaglandin-E2 9-reductase EC 1.1.1.190: indole-3-acetaldehyde reductase (NADH) EC 1.1.1.191: indole-3-acetaldehyde reductase (NADPH) EC 1.1.1.192: long-chain-alcohol dehydrogenase EC 1.1.1.193: 5-amino-6-(5-phosphoribosylamino)uracil reductase EC 1.1.1.194: coniferyl-alcohol dehydrogenase EC 1.1.1.195: cinnamyl-alcohol dehydrogenase EC 1.1.1.196: 15-hydroxyprostaglandin-D dehydrogenase (NADP+) EC 1.1.1.197: 15-hydroxyprostaglandin dehydrogenase (NADP+) EC 1.1.1.198: (+)-borneol dehydrogenase EC 1.1.1.199: (S)-usnate reductase EC 1.1.1.200: aldose-6-phosphate reductase (NADPH) EC 1.1.1.228: (+)-sabinol dehydrogenase EC 1.1.1.251: galactitol-1-phosphate 5-dehydrogenase EC 1.1.1.252: tetrahydroxynaphthalene reductase EC 1.1.1.253: Now EC 1.5.1.33, pteridine reductase EC 1.1.1.254: (S)-carnitine 3-dehydrogenase EC 1.1.1.255: mannitol dehydrogenase EC 1.1.1.256: fluoren-9-ol dehydrogenase EC 1.1.1.257: 4-(hydroxymethyl)benzenesulfonate dehydrogenase EC 1.1.1.258: 6-hydroxyhexanoate dehydrogenase EC 1.1.1.259: 3-hydroxypimeloyl-CoA dehydrogenase EC 1.1.1.260: sulcatone reductase EC 1.1.1.261: sn-glycerol-1-phosphate dehydrogenase EC 1.1.1.262: 4-hydroxythreonine-4-phosphate dehydrogenase EC 1.1.1.263: 1,5-anhydro-D-fructose reductase EC 1.1.1.264: L-idonate 5-dehydrogenase EC 1.1.1.265: 3-methylbutanal reductase EC 1.1.1.266: dTDP-4-dehydro-6-deoxyglucose reductase EC 1.1.1.267: 1-deoxy-D-xylulose-5-phosphate reductoisomerase EC 1.1.1.268: 2-(R)-hydroxypropyl-CoM dehydrogenase EC 1.1.1.269: 2-(S)-hydroxypropyl-CoM dehydrogenase EC 1.1.1.270: 3β-hydroxysteroid 3-dehydrogenase EC 1.1.1.271: GDP-L-fucose synthase EC 1.1.1.272: D-2-hydroxyacid dehydrogenase (NADP+) EC 1.1.1.273: vellosimine dehydrogenase EC 1.1.1.274: 2,5-didehydrogluconate reductase (2-dehydro-D-gluconate-forming) EC 1.1.1.275: (+)-trans-carveol dehydrogenase EC 1.1.1.276: serine 3-dehydrogenase (NADP+) EC 1.1.1.277: 3β-hydroxy-5β-steroid dehydrogenase EC 1.1.1.278: 3β-hydroxy-5α-steroid dehydrogenase EC 1.1.1.279: (R)-3-hydroxyacid-ester dehydrogenase EC 1.1.1.280: (S)-3-hydroxyacid-ester dehydrogenase EC 1.1.1.281: GDP-4-dehydro-6-deoxy-D-mannose reductase EC 1.1.1.282: Quinate/shikimate dehydrogenase EC 1.1.1.283: methylglyoxal reductase (NADPH-dependent) EC 1.1.1.284: S-(hydroxymethyl)glutathione dehydrogenase EC 1.1.1.285: 3′′-deamino-3′′-oxonicotianamine reductase EC 1.1.1.286: isocitrate—homoisocitrate dehydrogenase EC 1.1.1.287: D-arabinitol dehydrogenase (NADP+) EC 1.1.1.288: xanthoxin dehydrogenase EC 1.1.1.289: sorbose reductase EC 1.1.1.290: 4-phosphoerythronate dehydrogenase EC 1.1.1.291: 2-hydroxymethylglutarate dehydrogenase EC 1.1.1.292: 1,5-anhydro-D-fructose reductase (1,5-anhydro-D-mannitol-forming) EC 1.1.1.293: tropinone reductase I. This enzyme was already in the Enzyme List as EC 1.1.1.206, tropine dehydrogenase so EC 1.1.1.293 has been withdrawn at the public-review stage EC 1.1.1.294: chlorophyll(ide) b reductase EC 1.1.1.295: momilactone-A synthase EC 1.1.1.296: dihydrocarveol dehydrogenase EC 1.1.1.297: limonene-1,2-diol dehydrogenase EC 1.1.1.298: 3-hydroxypropionate dehydrogenase (NADP+) EC 1.1.1.299: malate dehydrogenase [NAD(P)+)] EC 1.1.1.300: NADP-retinol dehydrogenase EC 1.1.1.301: D-arabitol-phosphate dehydrogenase EC 1.1.1.302: 2,5-diamino-6-(ribosylamino)-4(3H)-pyrimidinone 5′-phosphate reductase EC 1.1.1.303: Diacetyl reductase ((R)-acetoin forming) EC 1.1.1.304: Diacetyl reductase ((S)-acetoin forming) EC 1.1.1.305: UDP-glucuronic acid dehydrogenase (UDP-4-keto-hexauronic acid decarboxylating) EC 1.1.1.306: S-(hydroxymethyl)mycothiol dehydrogenase EC 1.1.1.307: D-xylose reductase EC 1.1.1.308: sulfopropanediol 3-dehydrogenase EC 1.1.1.309: phosphonoacetaldehyde reductase (NADH) EC 1.1.1.310: (S)-sulfolactate dehydrogenase EC 1.1.1.311: (S)-1-phenylethanol dehydrogenase EC 1.1.1.312: 2-hydroxy-4-carboxymuconate semialdehyde hemiacetal dehydrogenase EC 1.1.1.313: sulfoacetaldehyde reductase EC 1.1.1.314: Now known to be catalyzed by EC 1.14.14.95, germacrene A hydroxylase EC 1.1.1.315: 11-cis-retinol dehydrogenase EC 1.1.1.316: L-galactose 1-dehydrogenase EC 1.1.1.317: perakine reductase EC 1.1.1.318: eugenol synthase EC 1.1.1.319: isoeugenol synthase EC 1.1.1.320: benzil reductase [(S)-benzoin forming] EC 1.1.1.321: benzil reductase [(R)-benzoin forming] EC 1.1.1.322: (–)-endo-fenchol dehydrogenase EC 1.1.1.323: (+)-thujan-3-ol dehydrogenase EC 1.1.1.324: 8-hydroxygeraniol dehydrogenase EC 1.1.1.325: sepiapterin reductase (L-threo-7,8-dihydrobiopterin forming) EC 1.1.1.326: zerumbone synthase EC 1.1.1.327: 5-exo-hydroxycamphor dehydrogenase EC 1.1.1.328: nicotine blue oxidoreductase EC 1.1.1.329: 2-deoxy-scyllo-inosamine dehydrogenase EC 1.1.1.330: very-long-chain 3-oxoacyl-CoA reductase EC 1.1.1.331: secoisolariciresinol dehydrogenase EC 1.1.1.332: chanoclavine-I dehydrogenase EC 1.1.1.333: decaprenylphospho-β-D-erythro-pentofuranosid-2-ulose 2-reductase EC 1.1.1.334: methylecgonone reductase EC 1.1.1.335: UDP-N-acetyl-2-amino-2-deoxyglucuronate dehydrogenase EC 1.1.1.336: UDP-N-acetyl-D-mannosamine dehydrogenase EC 1.1.1.337: L-2-hydroxycarboxylate dehydrogenase (NAD+) EC 1.1.1.338: (2R)-3-sulfolactate dehydrogenase (NADP+) EC 1.1.1.339: dTDP-6-deoxy-L-talose 4-dehydrogenase (NAD+) EC 1.1.1.340: 1-deoxy-11β-hydroxypentalenate dehydrogenase EC 1.1.1.341: CDP-abequose synthase EC 1.1.1.342: CDP-paratose synthase EC 1.1.1.343: phosphogluconate dehydrogenase (NAD+-dependent, decarboxylating) EC 1.1.1.344: dTDP-6-deoxy-L-talose 4-dehydrogenase [NAD(P)+] EC 1.1.1.345: D-2-hydroxyacid dehydrogenase (NAD+) EC 1.1.1.346: 2,5-didehydrogluconate reductase (2-dehydro-L-gulonate-forming) EC 1.1.1.347: geraniol dehydrogenase (NAD+) EC 1.1.1.348: (3R)-2′-hydroxyisoflavanone reductase EC 1.1.1.349: norsolorinic acid ketoreductase EC 1.1.1.350: ureidoglycolate dehydrogenase (NAD+) EC 1.1.1.351: phosphogluconate dehydrogenase [NAD(P)+-dependent, decarboxylating] EC 1.1.1.352: 5′-hydroxyaverantin dehydrogenase EC 1.1.1.353: versiconal hemiacetal acetate reductase EC 1.1.1.354: farnesol dehydrogenase (NAD+) EC 1.1.1.355: 2′-dehydrokanamycin reductase EC 1.1.1.356: GDP-L-colitose synthase EC 1.1.1.357: 3α-hydroxysteroid 3-dehydrogenase EC 1.1.1.358: 2-dehydropantolactone reductase EC 1.1.1.359: aldose 1-dehydrogenase [NAD(P)+] EC 1.1.1.360: glucose/galactose 1-dehydrogenase EC 1.1.1.361: glucose-6-phosphate 3-dehydrogenase EC 1.1.1.362: aklaviketone reductase EC 1.1.1.363: glucose-6-phosphate dehydrogenase [NAD(P)+] EC 1.1.1.364: dTDP-4-dehydro-6-deoxy-α-D-gulose 4-ketoreductase EC 1.1.1.365: D-galacturonate reductase EC 1.1.1.366: L-idonate 5-dehydrogenase (NAD+) EC 1.1.1.367: UDP-2-acetamido-2,6-β-L-arabino-hexul-4-ose reductase EC 1.1.1.368: 6-hydroxycyclohex-1-ene-1-carbonyl-CoA dehydrogenase EC 1.1.1.369: D-chiro-inositol 1-dehydrogenase EC 1.1.1.370: scyllo-inositol 2-dehydrogenase (NAD+) EC 1.1.1.371: scyllo-inositol 2-dehydrogenase (NADP+) EC 1.1.1.372: D/L-glyceraldehyde reductase EC 1.1.1.373: sulfolactaldehyde 3-reductase EC 1.1.1.374: UDP-N-acetylglucosamine 3-dehydrogenase EC 1.1.1.375: L-2-hydroxycarboxylate dehydrogenase [NAD(P)+] EC 1.1.1.376: L-arabinose 1-dehydrogenase [NAD(P)+] EC 1.1.1.377: L-rhamnose 1-dehydrogenase (NADP+) EC 1.1.1.378: L-rhamnose 1-dehydrogenase [NAD(P)+] EC 1.1.1.379: (R)-mandelate dehydrogenase EC 1.1.1.380: L-gulonate 5-dehydrogenase EC 1.1.1.381: 3-hydroxy acid dehydrogenase EC 1.1.1.382: ketol-acid reductoisomerase (NAD+) EC 1.1.1.383: ketol-acid reductoisomerase [NAD(P)+] EC 1.1.1.384: dTDP-3,4-didehydro-2,6-dideoxy-α-D-glucose 3-reductase EC 1.1.1.385: dihydroanticapsin dehydrogenase EC 1.1.1.386: ipsdienol dehydrogenase EC 1.1.1.387: L-serine 3-dehydrogenase (NAD+) EC 1.1.1.388: glucose-6-phosphate dehydrogenase (NAD+) EC 1.1.1.389: 2-dehydro-3-deoxy-L-galactonate 5-dehydrogenase EC 1.1.1.390: sulfoquinovose 1-dehydrogenase EC 1.1.1.391: 3β-hydroxycholanate 3-dehydrogenase (NAD+) EC 1.1.1.392: 3α-hydroxycholanate dehydrogenase (NADP+) EC 1.1.1.393: 3β-hydroxycholanate 3-dehydrogenase (NADP+) EC 1.1.1.394: aurachin B dehydrogenase EC 1.1.1.395: 3α-hydroxy bile acid-CoA-ester 3-dehydrogenase EC 1.1.1.396: bacteriochlorophyllide a dehydrogenase EC 1.1.1.397: β-methylindole-3-pyruvate reductase EC 1.1.1.398: 2-glutathionyl-2-methylbut-3-en-1-ol dehydrogenase EC 1.1.1.399: 2-oxoglutarate reductase EC 1.1.1.400: 2-methyl-1,2-propanediol dehydrogenase EC 1.1.1.401: 2-dehydro-3-deoxy-L-rhamnonate dehydrogenase (NAD+) EC 1.1.1.402: D-erythritol 1-phosphate dehydrogenase EC 1.1.1.403: D-threitol dehydrogenase (NAD+) EC 1.1.1.404: tetrachlorobenzoquinone reductase EC 1.1.1.405: ribitol-5-phosphate 2-dehydrogenase (NADP+) EC 1.1.1.406: galactitol 2-dehydrogenase (L-tagatose-forming) EC 1.1.1.407: D-altritol 5-dehydrogenase EC 1.1.1.408: 4-phospho-D-threonate 3-dehydrogenase EC 1.1.1.409: 4-phospho-D-erythronate 3-dehydrogenase EC 1.1.1.410: D-erythronate 2-dehydrogenase EC 1.1.1.411: L-threonate 2-dehydrogenase EC 1.1.1.412: 2-alkyl-3-oxoalkanoate reductase EC 1.1.1.413: A-factor type γ-butyrolactone 1′-reductase (1S-forming) EC 1.1.1.414: L-galactonate 5-dehydrogenase EC 1.1.1.415: noscapine synthase EC 1.1.1.416: isopyridoxal dehydrogenase (5-pyridoxolactone-forming) EC 1.1.1.417: 3β-hydroxysteroid-4β-carboxylate 3-dehydrogenase (decarboxylating) EC 1.1.1.418: plant 3β-hydroxysteroid-4α-carboxylate 3-dehydrogenase (decarboxylating) EC 1.1.1.419: nepetalactol dehydrogenase EC 1.1.1.420: D-apiose dehydrogenase EC 1.1.1.421: D-apionate oxidoisomerase EC 1.1.1.422: pseudoephedrine dehydrogenase EC 1.1.1.423: (1R,2S)-ephedrine 1-dehydrogenase EC 1.1.1.424: D-xylose 1-dehydrogenase (NADP+, D-xylono-1,4-lactone-forming) EC 1.1.1.425: levoglucosan dehydrogenase EC 1.1.1.426: UDP-N-acetyl-α-D-quinovosamine dehydrogenase
== Diagnosis == Joint hypermobility syndrome shares symptoms with other conditions such as Marfan syndrome and Ehlers-Danlos Syndrome. Hypermobility syndrome and Hypermobile Ehlers-Danlos syndrome are difficult to diffentiate, and the boundaries between them may be arbitrary. Hypermobility syndrome and hypermobile Ehlers-Danlos syndrome are both likely to have a variety of genetic causes. Generalized hypermobility is a common feature in hereditary connective tissue disorders and many features overlap, but often features are present that enable differentiating these disorders. Ehlers-Danlos Syndrome was defined based on its observable symptoms in the skin and joints. The inheritance pattern of Ehlers-Danlos syndrome varies by type. The arthrochalasia, classic, hypermobility and vascular forms usually have an autosomal dominant pattern of inheritance. Autosomal dominant inheritance occurs when one copy of a gene in each cell is sufficient to cause a disorder. In some cases, an affected person inherits the mutation from one affected parent. Other cases result from new (sporadic) gene mutations. Such cases can occur in people with no history of the disorder in their family. It is impossible to tell whether a person has EDS symptoms due to an inherited EDS gene, a spontaneous mutation that causes identical symptoms, or a problem in fetal development causes identical symptoms, without both knowing the genetic family history and performing a specialized genetic test. The results do not matter to clinical treatment of the symptoms.
Depolarization opens both the sodium and potassium channels in the membrane, allowing the ions to flow into and out of the axon, respectively. If the depolarization is small (say, increasing Vm from −70 mV to −60 mV), the outward potassium current overwhelms the inward sodium current and the membrane repolarizes back to its normal resting potential around −70 mV. However, if the depolarization is large enough, the inward sodium current increases more than the outward potassium current and a runaway condition (positive feedback) results: the more inward current there is, the more Vm increases, which in turn further increases the inward current. A sufficiently strong depolarization (increase in Vm) causes the voltage-sensitive sodium channels to open; the increasing permeability to sodium drives Vm closer to the sodium equilibrium voltage ENa≈ +55 mV. The increasing voltage in turn causes even more sodium channels to open, which pushes Vm still further towards ENa. This positive feedback continues until the sodium channels are fully open and Vm is close to ENa. The sharp rise in Vm and sodium permeability correspond to the rising phase of the action potential. The critical threshold voltage for this runaway condition is usually around −45 mV, but it depends on the recent activity of the axon. A cell that has just fired an action potential cannot fire another one immediately, since the Na+ channels have not recovered from the inactivated state. The period during which no new action potential can be fired is called the absolute refractory period.
Xi has ruled out a multi-party system for China, saying that "constitutional monarchy, imperial restoration, parliamentarism, a multi-party system and a presidential system, we considered them, tried them, but none worked." However, Xi considers China to be a democracy, saying that "China's socialist democracy is the most comprehensive, genuine and effective democracy." China's definition of democracy is different from liberal democracies and is rooted in Marxism–Leninism, and is based on the phrases people's democratic dictatorship and democratic centralism. Xi has additionally coined the term whole-process people's democracy which he said was about having "the people as masters". Foreign analysts and observers have widely disputed that China is a democracy, saying that it is a one-party authoritarian state and Xi an authoritarian leader. Xi has sometimes referred to as "traditionalist" or "neo-authoritarian". Xi has additionally rejected Westernisation as the only way to modernize, instead promoting what he says is Chinese modernization.
Sources: en.wikipedia.org
Patient-centric definitions, generally independent of changes in technology Concepts with references to established international definitions Definitions specifying measurement units (with preference for SI) and measured properties Consistent with the principles outlined in the International Vocabulary of Metrology (VIM) and Vocabulary for Nominal Properties and Nominal Examinations (VIN) Broad membership of guiding NPU committee with extensive expertise in the biological and chemical sciences and the principles of nomenclature.
To overcome this, GLP-1 receptor agonists and DPP-4 inhibitors have been developed to increase GLP-1 activity. As opposed to common treatment agents such as insulin and sulphonylureas, GLP-1-based treatment has been associated with weight loss and a lower risk of hypoglycemia, two important considerations for patients with type 2 diabetes.
Fifty years after the introduction of fluoxetine and other SSRIs, these drugs remain widely used and effective for depression. Concerns about over prescription, under-treatment of depression through other modalities, and role in the over-medicalization of normal life remain debated.
Sargramostim, sold under the brand name Leukine among others, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that functions as an immunostimulator. It is administered via intravenous infusion or via subcutaneous injection.
The genetic code (the "translation table" according to which DNA information is translated into amino acids, and hence proteins) is nearly identical for all known lifeforms, from bacteria and archaea to animals and plants. The universality of this code is generally regarded by biologists as definitive evidence in favor of universal common descent. The way that codons (DNA triplets) are mapped to amino acids seems to be strongly optimised. Richard Egel argues that in particular the hydrophobic (non-polar) side-chains are well organised, suggesting that these enabled the earliest organisms to create peptides with water-repelling regions able to support the essential electron exchange (redox) reactions for energy transfer.
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius with protection from light is the common recommendation. Many laboratories choose frozen storage at minus 20 degrees Celsius when the material will not be used soon. Repeated temperature cycling is generally avoided.
Mass spectrometry gives the observed mass, which is compared against the value calculated from the sequence. Peptide mapping after digestion provides a second, sequence-level check. Chromatographic retention alone is not sufficient for identity.
Antibodies raised against one GHRH-related peptide may bind other members of the same family. That cross-reactivity inflates or distorts measured concentrations. Assay validation with defined standards is therefore necessary before results are interpreted.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.